Gaudium IVF and Women Health Limited
All news and filings related to Gaudium IVF and Women Health Limited.
View all news & filings- Medium impact
Gaudium IVF's 11th AGM Concludes: All Resolutions Approved by Shareholders
Gaudium IVF's 11th AGM on September 28, 2026, approved all resolutions. Key approvals include financial statements, director re-appointments, and remuneration adjustments for key management personnel. The company also appointed secretarial auditors for a five-year term.
Read the summary - Low impact
Gaudium IVF holds 11th AGM on Sep 28, 2026, transacting all businesses
Gaudium IVF held its 11th AGM on Sep 28, 2026, transacting all businesses. Key agenda items included adopting FY26 financial statements and approving director re-appointments and remuneration. The meeting highlighted the company's listing, financial performance, and strategic growth initiatives.
Read the summary - Low impact
Gaudium IVF Closes Trading Window from Oct 1, 2026, for Q2 FY27 Financial Results
Gaudium IVF will close its trading window from October 01, 2026. The window will reopen 48 hours after the announcement of Q2 FY27 financial results. The board meeting date for approving these results will be announced later.
Read the summary - Medium impact
Gaudium IVF Commences Operations at New Gurgaon Centre
Gaudium IVF and Women Health Limited has commenced operations at its new IVF Centre/Hub in Gurgaon, Haryana, effective September 24, 2026. The facility aims to provide comprehensive fertility and reproductive healthcare services, integrating advanced embryology and AI-powered technologies.
Read the summary - Low impact
Gaudium IVF Announces 11th AGM on Sep 28, 2026, and Dispatches Annual Report
Gaudium IVF and Women Health Limited will hold its 11th AGM on September 28, 2026, via video conference. The company has dispatched its Annual Report for FY 2025-26 to shareholders. Remote e-voting will be open from September 25 to September 27, 2026.
Read the summary - Medium impact
Gaudium IVF Announces 11th AGM on Sep 28, 2026, to Discuss FY26 Financials and Director Re-appointment
Gaudium IVF will hold its 11th AGM on September 28, 2026, to adopt FY26 financial statements. Key agenda items include re-appointing Mr. Vishad Khanna, revising remuneration for Dr. Peeyush Khanna (₹48 Lakhs salary, ₹36 Lakhs consultancy) and Dr. Manika Khanna (₹1.8 Crore consultancy), and appointing secretarial auditors for five years.
Read the summary - Low impact
Gaudium IVF Announces 11th AGM on Sep 28, 2026, via VC/OAVM
Gaudium IVF and Women Health Limited will hold its 11th AGM on September 28, 2026, via VC/OAVM. The company will dispatch the AGM notice and annual report electronically to registered members. E-voting facilities will be provided through NSDL.
Read the summary - Medium impact
Gaudium IVF Q1 FY27 Revenue Up 9.1% to ₹19.4 Cr, Focus on Expansion
Gaudium IVF reported Q1 FY27 revenue of ₹19.4 Cr, a 9.1% YoY increase. The company is investing heavily in expansion, planning 27 new hubs. Clinical success rates improved to 62% with AI integration. Gaudium IVF targets 30% revenue growth for FY27 and expects new hubs to break even within 3 months. A new women's hospital in Lucknow is also approved.
Read the summary - Low impact
Gaudium IVF Uploads Q1 FY27 Earnings Call Audio Recording
Gaudium IVF and Women Health Limited has made available the audio recording of its earnings call for the quarter ended June 30, 2026. The call took place on August 14, 2026, and the recording can be accessed via the company's website.
Read the summary - Low impact
Gaudium IVF Announces Unaudited Financial Results for Q1 FY27
Gaudium IVF and Women Health Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were approved by the Board on August 13, 2026, and published in newspapers on August 14, 2026. Full details are available on the company and stock exchange websites.
Read the summary - Medium impact
Gaudium IVF Revises Investor Presentation for Q1 FY27 with Financial Updates
Gaudium IVF revised its Q1 FY27 investor presentation, adding a one-time marketing cost of ₹253.24 lakhs for SID and ERICA. Adjusted EBITDA for standalone results is ₹507.75 lakhs (37.12% margin), and for consolidated results, it is ₹532.75 lakhs (27.49% margin). The company attributes performance moderation to expansion costs.
Read the summary - Medium impact
Gaudium IVF Q1 FY27 Investor Presentation: Financial Results and Expansion Plans
Gaudium IVF presented its Q1 FY27 investor results, highlighting consolidated revenue of ₹1,937.66 lakhs. The company is investing in expansion with new hubs planned for FY27. Management attributes current financial moderation to strategic investments in growth initiatives and AI-led technologies. The presentation also details industry growth drivers and Gaudium's competitive strengths.
Read the summary - Low impact
Gaudium IVF Schedules Q1 FY27 Earnings Call for August 14, 2026
Gaudium IVF and Women Health Limited will hold an Earnings Conference Call on August 14, 2026, at 2:00 PM IST to discuss its Q1 FY27 unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Key management will participate.
Read the summary - Medium impact
Gaudium IVF Launches AI-Powered Signature Labs, Begins 19-Centre Expansion
Gaudium IVF has launched its first AI-powered Signature Lab in South Delhi, initiating its planned 19-centre expansion. This launch integrates AI-assisted embryology and globally benchmarked laboratory standards to enhance fertility care accessibility and quality across its network.
Read the summary - Medium impact
Gaudium IVF Commences Operations at New Delhi Centre on July 16, 2026
Gaudium IVF and Women Health Limited will commence operations at its new IVF Centre/Hub in South Extension, New Delhi, on July 16, 2026. The facility aims to provide advanced fertility and reproductive healthcare services.
Read the summary - Low impact
Gaudium IVF: Compliance Certificate for Q1 FY27 Confirms Shares in Demat Form
Gaudium IVF and Women Health Limited received a compliance certificate for the quarter ended June 30, 2026. The certificate confirms that Regulation 74(5) of SEBI is not applicable as all shares are in demat form and no rematerialization or dematerialization requests were received.
Read the summary - Low impact
Gaudium IVF Promoter Group Declares No Share Encumbrance for FY26
Gaudium IVF promoter Dr. Manika Khanna declared no share encumbrance by promoters or persons acting in concert for FY26. The declaration is under SEBI (SAST) Regulations. A list of promoter and promoter group members is provided.
Read the summary - Low impact
Gaudium IVF: Promoter Group Confirms No Share Encumbrance for FY26
Gaudium IVF and Women Health Limited disclosed that its promoter group has not encumbered any shares as of March 31, 2026. This annual filing under SEBI Takeover Regulations confirms no indirect or direct encumbrance on the company's shares by promoters or persons acting in concert.
Read the summary - Low impact
Gaudium IVF: Audio Recording of Q4 FY26 Earnings Call Now Available Online
Gaudium IVF released the audio recording of its Q4 FY26 earnings call on May 29, 2026. The call covered audited standalone and consolidated financial results for the quarter and year ending March 31, 2026. The recording is available on the company's website.
Read the summary - Low impact
Gaudium IVF Publishes Audited Financial Results for Q4 and FY26
Gaudium IVF and Women Health Limited announced its audited financial results for the quarter and year ended March 31, 2026. The results were approved by the Board on May 28, 2026, and published on May 29, 2026. The detailed financial statements are available on the company's website and stock exchanges.
Read the summary - High impact
Gaudium IVF Q4 & FY26 Results: Revenue Jumps 47.56% to ₹10,435.70 Lakhs
Gaudium IVF reported strong financial results for Q4 and FY26. Consolidated revenue surged 47.56% to ₹10,435.70 Lakhs for FY26. PAT from continuing operations grew 27.69% to ₹2,448.85 Lakhs. Standalone revenue increased 21.32% to ₹7,157.85 Lakhs for FY26. The growth was driven by higher patient volumes and improved operational efficiencies.
Read the summary - High impact
Gaudium IVF Q4FY26 Revenue Surges 12.7% YoY to ₹30.35 Cr; PAT Jumps 29.5%
Gaudium IVF reported Q4FY26 revenue of ₹30.35 Cr, up 12.7% YoY. FY26 revenue grew 47.6% to ₹104.35 Cr. Q4FY26 PAT rose 29.5% to ₹8.36 Cr, and FY26 PAT increased 27.7% to ₹24.48 Cr. The company adopted AI-led embryology in April 2026. It plans to open 10 new IVF hubs in FY27.
Read the summary - Medium impact
Gaudium IVF Board Approves Audited FY26 Standalone & Consolidated Financial Results
Gaudium IVF's Board approved audited standalone and consolidated results for FY26, ending March 31, 2026. Standalone profit before tax was ₹2,926.55 lakhs, while consolidated profit before tax was ₹3,219.56 lakhs. The company also announced a trading window closure until May 30, 2026.
Read the summary - Low impact
Gaudium IVF NCLT Petition Rejection: Petition filed by Ramaa Capital rejected by NCLT
Gaudium IVF & Women Health announced that the National Company Law Tribunal (NCLT), New Delhi Bench, rejected the petition filed by Ramaa Capital under Section 9 of the Insolvency and Bankruptcy Code. The order was passed on May 15, 2026, and the company received the order on May 22, 2026. The company stated that there is no impact on financial or operational activities.
Read the summary - Low impact
Gaudium IVF Schedules Q4 & FY26 Earnings Call for May 29, 2026
Gaudium IVF and Women Health Limited will host an Earnings Conference Call on May 29, 2026, at 12:00 PM IST to discuss financial results for the quarter and year ended March 31, 2026. Management participants will include the Chairperson & MD, Whole-Time Director, and CFO.
Read the summary - Low impact
Gaudium IVF Files Monitoring Agency Report for Q4 FY26, IPO Proceeds Utilization Under Review
Gaudium IVF and Women Health Limited submitted its Monitoring Agency Report for the quarter ended March 31, 2026. The report covers the utilization of IPO proceeds amounting to ₹90.00 crore. During the quarter, ₹8.69 crore was utilized, with ₹0.97 crore for general corporate purposes and ₹7.72 crore for issue expenses. A significant portion of IPO proceeds remains unutilized.
Read the summary - Low impact
Gaudium IVF Clarifies Price Movement, Cites Market Driven Factors
Gaudium IVF and Women Health Limited clarified to stock exchanges that recent share price movements are market-driven. The company confirmed no undisclosed price-sensitive information or impending corporate actions are pending. It reiterated its commitment to timely disclosure of material information as per SEBI regulations.
Read the summary - Low impact
Gaudium IVF Changes Corporate Identification Number to L85100DL2015PLC278296, Status Updated to Listed
Gaudium IVF and Women Health Limited's Corporate Identification Number (CIN) changed from U85100DL2015PLC278296 to L85100DL2015PLC278296. The company's status has been updated from 'Unlisted' to 'Listed' following its listing on NSE and BSE. Authorized capital is ₹44 crore, paid-up capital is ₹36.39 crore.
Read the summary - Low impact
Gaudium IVF: Regulation 74(5) Compliance Certificate for Q4 FY26 Issued
Gaudium IVF and Women Health Limited received a compliance certificate for the quarter ended March 31, 2026. The Registrar and Transfer Agent confirmed that Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, is not applicable as all shares are in demat form.
Read the summary - Low impact
Gaudium IVF: Arbitration Petition Disposed, Sole Arbitrator Appointed
Gaudium IVF's arbitration petition with Neomile Corporate Advisory Limited has been disposed of by the Bombay High Court. Mr. Justice Nitin Jamdar has been appointed as the Sole Arbitrator. Dr. Manika Khanna is also a party. No financial implications are reported at this stage.
Read the summary - Low impact
Gaudium IVF: Arbitration Petition Disposed, Sole Arbitrator Appointed
Gaudium IVF's arbitration petition filed by Neomile Corporate Advisory Limited has been disposed of by the Bombay High Court. Mr. Justice Nitin Jamdar has been appointed as the Sole Arbitrator. Dr. Manika Khanna, CMD, is also a party. No financial implications at this stage.
Read the summary - Medium impact
Gaudium IVF Launches AI-Led Infertility Treatment, an Industry First in India
Gaudium IVF has introduced AI-led infertility treatment with advanced embryology systems SiD and ERICA. This collaboration with UK-based IVF 2.0 aims to improve treatment success rates and patient outcomes. The launch was inaugurated by Hon’ble Union Minister Shri Nitin Jairam Gadkari.
Read the summary - Medium impact
Gaudium IVF faces ₹29.2 crore arbitration claim from Neomile Corporate Advisory
Gaudium IVF and Women Health Limited is facing an arbitration proceeding initiated by Neomile Corporate Advisory Limited. The claim amounts to ₹29.2 crore for alleged advisory services related to the company's IPO. Gaudium IVF considers the claim frivolous and unsubstantiated.
Read the summary - Low impact
Gaudium IVF Closes Trading Window from April 1, 2026, for Q4 FY26 Financial Results
Gaudium IVF and Women Health Limited will close its trading window from April 1, 2026. This is in compliance with SEBI regulations for insider trading. The window will reopen 48 hours after the announcement of the financial results for the quarter and year ended March 31, 2026.
Read the summary - Medium impact
Gaudium IVF Q3 FY26 Net Profit at ₹3.63 Crore, Revenue at ₹24.51 Crore
Gaudium IVF reported Q3 FY26 unaudited results with net profit at ₹3.63 crore and revenue at ₹24.51 crore. For 9M FY26, net profit was ₹16.15 crore on revenue of ₹74.01 crore. The company successfully completed its IPO, raising ₹165.00 crore and listing on exchanges on February 27, 2026.
Read the summary - Low impact
Gaudium IVF announces Q3 & 9M FY26 Unaudited Financial Results
Gaudium IVF and Women Health Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on March 18, 2026. The results were published in Financial Express and Jansatta on March 19, 2026 and are available on the company's website.
Read the summary - Low impact
Gaudium IVF Appoints Ram Rattan & Associates and Suresh Nainwal & Co.
Gaudium IVF and Women Health Limited appointed M/s. Ram Rattan & Associates as Internal Auditors and M/s. Suresh Nainwal & Company as Secretarial Auditors for FY 2025-2026. The appointments were approved by the Board of Directors on March 18, 2026.
Read the summary - Medium impact
Gaudium IVF Q3 FY26 Consolidated Revenue ₹246.10 Crore, Net Profit ₹363.08 Lakhs
Gaudium IVF reported Q3 FY26 consolidated revenue of ₹246.10 crore and net profit of ₹363.08 Lakhs. For nine months ended Dec 31, 2025, consolidated revenue was ₹743.60 crore with net profit of ₹1,614.90 Lakhs. Standalone Q3 revenue was ₹142.97 crore, net profit ₹18.40 Lakhs. Trading window closed until March 20, 2026.
Read the summary - Low impact
Gaudium IVF Authorizes Key Personnel for Materiality Determinations and Disclosures
Gaudium IVF's Board has authorized Dr. Manika Khanna, Mr. Rakesh Kumar Sharma, and Mr. Naveen Kumar to determine materiality and make disclosures to stock exchanges as per SEBI Listing Regulations.
Read the summary - Low impact
Gaudium IVF Adopts Code for Fair Disclosure of UPSI
Gaudium IVF and Women Health Limited has adopted a Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI). Approved on November 4, 2024, the code ensures timely and transparent disclosure of material information to stakeholders and outlines procedures for handling UPSI.
Read the summary - Low impact
Gaudium IVF Appoints Bigshare Services as Registrar and Share Transfer Agent
Gaudium IVF and Women Health Limited has appointed Bigshare Services Private Limited as its Registrar and Share Transfer Agent. This appointment is in compliance with SEBI Listing Regulations, ensuring continued adherence to regulatory requirements for share transfer and related services.
Read the summary - Low impact
Gaudium IVF Appoints Naveen Kumar as Compliance Officer
Gaudium IVF and Women Health Limited appointed Mr. Naveen Kumar as Compliance Officer and Company Secretary, effective November 04, 2024, as per SEBI regulations.
Read the summary - Low impact
Gaudium IVF Closes Trading Window from Feb 27, 2026, pending Q3 FY26 Results
Gaudium IVF has closed its trading window for designated persons from February 27, 2026. This closure is effective until 48 hours after the announcement of the un-audited financial results for the quarter and nine months ended December 31, 2025. The board meeting date for results approval will be intimated separately.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio